Generation of flow cytometry data files with a potentially infinite number of dimensions

Cytometry Part A

Volumn 73, Issue 9, 2008, Pages 834-846

  Pedreira, Carlos E ^a   Costa, Elaine S ^a   Barrena, Susana ^b   Lecrevisse, Quentin ^b   Almeida, Julia ^b   Van Dongen, Jacques J M ^c   Orfao, Alberto ^b,d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b CSIC   (Spain)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

B cell chronic lymphoproliferative disorders; Data calculation; FCS files; Flow cytometry; Immunophenotyping; Nearest neighbor

Indexed keywords

CD19 ANTIGEN; FLUOROCHROME; MONOCLONAL ANTIBODY; REAGENT;

ADULT; AGED; ARTICLE; AUTOMATION; B CELL CHRONIC LYMPHOPROLIFERATIVE DISORDER; B LYMPHOCYTE; CELL SURFACE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STAINING; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; AUTOMATIC DATA PROCESSING; B-LYMPHOCYTES; BIOLOGICAL MARKERS; BONE MARROW; CHRONIC DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 51449109366     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20608     Document Type: Article

References (38)

1. DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998;25:6-10.
2. Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001;38:111-123.
3. Matutes E. New additions to antibody panels in the characterization of chronic lymphoproliferative disorders. J Clin Pathol 2002;55:180-183.
4. Braylan RC. Impact of flow cytometry on the diagnosis and characterization of lymphomas, chronic lymphoproliferative disorders and plasma cell neoplasias. Cytometry A 2004;58:57-61.
5. Kaleem Z. Flow cytometric analysis of lymphomas: Current status and usefulness. Arch Pathol Lab Med 2006;130:1850-1858.
6. Del Principe MI, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A, Marini R, Niscola P, Consalvo MA, Mazzone C, Ottaviani L, Panetta P, Bruno A, Bomben R, Suppo G, Degan M, Gattei V, de Fabritis P, Cantonetti M, Lo Coco F, del Principe D, Amadori S. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853-861.
7. Hayat A, O'Brien D, O'Rourke P, McGuckin S, Fitzgerald T, Conneally E, Browne PV, McCann SR, Lawler MP, Vandenberghe E. CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:2371-2379.
8. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP, Russel NH, Hale G, Morgan GJ, Jack AS, Hilmen P. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001;98:29-35.
9. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-cell antigen expression: Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001;2:300-306.
10. Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur DS, Lin Y, Stone D, Axworthy D, Gopal AK, Press ON. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20. CD22 and DR molecules on human B cell lymphomas. Blood 2007;109:4980-4987.
11. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, Hilmen P. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971-2979.
12. Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: The need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest 2005;23:488-496.
13. Sanchez ML, Almeida J, Lopez A, Sayagues JM, Rasillo A, Sarasquete EA, Balanzategui A, Tabernerg MD, Diaz-Mediavilla J, Barrachina C, Paiva A, Gonzalez M, San Miguel JF, Orfao A. Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: Biclonality versus intraclonal evolution of a single tumor cell clone. Haematologica 2006;91:331-339.
14. Sanchez ML, Almeida J, Gonzalez D, Gonzalez M, Garcia-Marcos MA, Balanzategui A, Lopez-Beges MC, Nomdedeu J, Vallespi T, Barbon M, Martin A, de la Fuente P, Martin-Nunez G, Fernandez-Calvo J, Hernandez JM, San Miguel JF, Orfao A. Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood 2003;102:2994-3002.
15. Sanchez ML, Almeida J, Vidriales B, Lopez-Berges MC, Garcia-Marcos MA, Moro MJ, Corrales A, Calmutia MJ, San Miguel JF, Orfao A. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: Basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002;16:1460-1469.
16. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: Results of an international consensus meeting. Cytometry 2001;46:23-27.
17. Gervasi F, Lo Verso R, Giambanco C, Cardinale G, Tomaselli C, Pagnucco G. Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites. Ann N Y Acad Sci 2004;1028:457-462.
18. Deneys V, Mazzon AM, Marques JL, Benoit H, De Bruyere M. Reference values for peripheral blood B-lymphocyte subpopulations: A basis for multiparametric immunophenotyping of abnormal lymphocytes. J Immunol Methods 2001;253:23-36.
19. Ashman M, Sachdeva N, Davila L, Scott G, Mitchell C, Cintron L, Rathore M, Asthana D. Influence of 4- and 6-color flow cytometers and acquisition/analysis softwares on the determination of lymphocyte subsets in HIV infection. Cytometry B Clin Cytom 2007;72:380-386.
20. Bigos M, Baumgarth N, Jager GC, Herman OC, Nozaki T, Stovel RT, Nozaki T, Parks D, Herzenberg L. Nine color eleven parameter immunophenotyping using three laser flow cytometry. Cytometry 1999;36:36-45.
21. Costa ES, Arroyo ME, Pedreira CE, García-Marcos MA, Tabernero MD, Almeida J, Orfao A. A new automated flow cytometry data analysis approach for the diagnostic screening of neoplastic B-cell disorders. Leukemia 2006;20:1221-1230.
22. Barlage S, Rothe G, Knuechel R, Schmitz G. Flow cytometric immunophenotyping of mature lymphatic neoplasias using knowledge guided cluster analysis. Anal Cell Pathol 1999;19:81-90.
23. Harris N, Jaffe E, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J, Lister TA, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematomoietic and lymphoid tissues: Report of the Clinical Advisory Comittee Meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849.
24. Robinson JP, Durack G, Kelley S. An innovation in flow cytometry data collection and analysis producing a correlated multiple sample analysis in a single file. Cytometry 1991;12:82-90.
25. Robinson JP, Ragheb K, Lawler G, Kelley S, Durack G. Rapid multivariate analysis and display of cross-reacting antibodies on human leukocytes. Cytometry 1992;13(1):75:82.
26. Cover TM, Hart PE. Nearest neighbor pattern classification. IEEE Trans Inf Theory 1967;13:21-27.
27. Duda RO, Hart PE, Stork DG, editors. Pattern Classification. New York, NY: Wiley; 2001.
28. Pagnucco G, Giambanco C, Gervasi F. The role of flow cytometric immunophenotyping in myelodysplastic syndromes. Ann N YAcad Sci 2006;1089:383-394.
29. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haaser D, Kolb HJ, Krieger O, Loken M, van de Loodrecht A, Ogata K, Orfao A, Pfeilstocken M, Ruter B, Sperr WR, Stauder R, Wells DA. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 2007;31:727-736.
30. Del Canizo MC, Fernandez ME, Lopez A, Vidriales B, Villaron E, Arroyo JL, Otuno F, Orfao A, San Miguel JF. Immunophenotypic analysis of myelodysplastic syndromes. Haematologica 2003;88:402-407.
31. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: Unravelling the immune system. Nat Rev Immunol 2004;4:648-655.
32. Tung JW, Parks DR, Moore WA, Herzenberg LA, Herzenberg LA. New approaches to fluorescence compensation and visualization of FACS data. Clin Immunol 2004;110:277-283.
33. Bakke AC, Purtzer Z, Leis J, Huang J. A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom 2006;70:227-234.
34. Macedo A, Orfao A, Ciudad J, Gonzalez M, Vidriales B, Lopez-Berges MC, Martinez A, Landolfi C, Canizo C, San Miguel JF. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 1995;9:1896-1901.
35. Wang L, Abbasi F, Gaigalas AK, Vogt RF, Marti GE. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells. Cytometry B Clin Cytom 2006;70:410-415.
36. Ortuño F, Ferrer F, Lozano ML, Heras I, Moraleda JM, Vicente V. Differences in phycoerythrin- or fluorescein-isothiocyanate conjugated 8G12 on CD34+ cell evaluation. Haematologica 1997;82:334-335.
37. Van Lochem EG, Groeneveld K, Te Marvelde JG, van den Beemd MW, Hooijkaas H, van Dongen JJ. Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes: Testing of a new fixation-permeabilization solution. Leukemia 1997;11:2208-2210.
38. Kappelmayer J, Gratama JW, Karaszi E, Menendez P, Ciudad J, Rivas R, Orfao A. Flow cytometric detection of intracellular myeloperoxidase. CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods 2000;242:53-65.